Anti-SARS-CoV-2 mAbs as Preexposure Prophylaxis Proof of Concept and Future Directions

Raymond R. Razonable, MD

This activity is jointly provided by Global Education Group and Integritas Communications.


This activity is supported by independent educational grants from AstraZeneca.


Raymund R. Razonable, MD, FIDSA, FAST 
Professor of Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic College of Medicine and Science
Rochester, Minnesota 

Target Audience 

The educational design of this activity addresses the needs of infectious disease specialists, internal medicine physicians, transplant specialists, oncologists, pharmacists, and other clinicians involved in managing patients who are at heightened risk for poor COVID-19 outcomes. 

Educational Objectives  

After completing this activity, the participant should be better able to:

  • Discuss recent trial data and current regulatory status for anti-SARS-CoV-2 monoclonal antibodies (mAbs) 
  • Create proactive plans with patients, other clinicians, and health care systems to ensure prompt and equitable use of COVID-19 therapies 

Program Description 

The rapidly evolving COVID-19 variants and subvariants have necessitated frequent changes to strategies for treatment and prevention of COVID-19 in immunocompromised patients. Ever-changing clinical guidelines, Emergency Use Authorization (EUA) status, and logistical implementation challenges, make it difficult for clinicians to stay current in this quickly evolving field. During this program, Dr. Raymund Razonable reviews the latest information on immune-evasive subvariants, both clinical data and changes to EUA status for monoclonal antibodies used for preexposure prophylaxis (PrEP), and looks at the future of PrEP and treatment for immunocompromised patients with COVID-19. 

Physician Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation 

Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse Practitioner Continuing Education 

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Disclosures of Relevant Financial Relationships 

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated. 

Raymund R. Razonable, MD, FIDSA, FAST: Contracted Research: Gilead Sciences, Inc. (funds to institution), F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc.; Honoraria: Member of DSMB for Novartis Pharmaceuticals Corporation 

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Instructions to Receive Credit 

In order to receive credit for this activity, the participant must score 100% on the posttest and complete the program evaluation. 

Global Contact Information 

For information about the approval of this program, please contact Global at 303-395-1782 or 

Fee Information & Refund/Cancellation Policy 

There is no fee for this educational activity. 

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.25

credit type CME/CE

release 03/10/2023

expiration 03/10/2024